FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease (original) (raw)

Model-Based Analysis of FGF23 Regulation in Chronic Kidney Disease

Joao Raposo

Gene Regulation and Systems Biology, 2010

View PDFchevron_right

High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients

Thierry Vanel

Nephrology Dialysis Transplantation, 2009

View PDFchevron_right

Cardiovascular Disease in Patients With Chronic Kidney Disease

Sandep Mahajan

American Journal of Kidney Diseases, 2012

View PDFchevron_right

FGF-23 and Phosphate in Children with Chronic Kidney Disease: A Cross-Sectional Study in Kazakhstan

Altynay Balmukhanova

Medicina-lithuania, 2020

View PDFchevron_right

Chronic kidney disease and the aging population

Miguel Riella

American Journal of Hypertension, 2014

View PDFchevron_right

Diagnosis and Management of Chronic Kidney Disease

Costas Fourtounas

Mayo Clinic Proceedings, 2008

View PDFchevron_right

Editorial: Molecular Mechanisms in Chronic Kidney Disease

Samar Abd ElHafeez

2021

View PDFchevron_right

Follistatin-Like-1 (FSTL1) Is a Fibroblast-Derived Growth Factor That Contributes to Progression of Chronic Kidney Disease

York Pei

International Journal of Molecular Sciences, 2021

View PDFchevron_right

Coronary Artery Disease in Patients with Chronic Kidney Disease: A Clinical Update

mostafa Dastani

Current Cardiology Reviews, 2014

View PDFchevron_right

Circulating fibroblast growth factor-23 plasma levels predict adverse cardiovascular outcomes in coronary artery disease patients with diabetes mellitus

Jesus Egido

Diabetes/Metabolism Research and Reviews, 2016

View PDFchevron_right

Fibroblast Growth Factor23 Mitigates Hyperphosphatemia but Accentuates Calcitriol Deficiency in Chronic Kidney Disease

Orlando Gutierrez

2005

View PDFchevron_right

The Importance of Tubular Function in Chronic Kidney Disease

Valentin Ramiro Sueiro

International Journal of Nephrology and Renovascular Disease, 2019

View PDFchevron_right

FGF21 increases water intake, urine output and blood pressure in rats

Matthew Zahner

PLOS ONE, 2018

View PDFchevron_right

Closing the gap between evidence and practice in chronic kidney disease

Mona Alrukhaimi

Kidney International Supplements, 2017

View PDFchevron_right

Chronic Kidney Disease: Physicians' Views and Approaches

shyam chirravoori

Hong Kong Journal of Nephrology, 2006

View PDFchevron_right

The risk of atherosclerosis in patients with chronic kidney disease

J. Rysz

International Urology and Nephrology, 2013

View PDFchevron_right

Chronic kidney disease: a new priority for primary care

Simon de Lusignan

The British journal of general practice : the journal of the Royal College of General Practitioners, 2006

View PDFchevron_right

“New” cardiovascular risk factors in patients with chronic kidney disease: Role of folic acid treatment

RAMON ROMERO

Kidney International, 2005

View PDFchevron_right

Risk factors for atherosclerosis in patients with chronic kidney disease:recognition and management

Martin Alpert

Current Opinion in Pharmacology, 2013

View PDFchevron_right

Serum levels of angiopoietin-related growth factor in diabetes mellitus and chronic hemodialysis

Hilmi Ataseven

Cumhuriyet medical journal, 2021

View PDFchevron_right

Risk Factors for End-Stage Renal Disease

Jeanne Darbinian

Archives of Internal Medicine, 2009

View PDFchevron_right

Urinary TGF-β1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy

Marcello Bertoluci

Diabetes Research and Clinical Practice, 2006

View PDFchevron_right

Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs

Nihad Tamimi

World Journal of Nephrology, 2014

View PDFchevron_right

FGF23 in patients with end-stage renal disease on hemodialysis

Yoshiki Nishizawa

Kidney International, 2004

View PDFchevron_right

FGF23 and Cardiovascular Structure and Function in Advanced Chronic Kidney Disease

Sahir Kalim

Kidney360

View PDFchevron_right

Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease

Janine Wirth

American Heart Journal, 2011

View PDFchevron_right

Angiotensin II and Renal Fibrosis

Jesus Egido

Hypertension, 2001

View PDFchevron_right

Pathogenesis of vascular calcification in chronic kidney disease

Diego Brancaccio

Kidney International, 2005

View PDFchevron_right

Cardiovascular events and death in Japanese patients with chronic kidney disease

Tadao Akizawa

Kidney International, 2017

View PDFchevron_right

Circulating levels of fibroblast growth factor-21 increase with age independently of body composition indices among healthy individuals

Ambika Ashraf

Journal of Clinical & Translational Endocrinology, 2015

View PDFchevron_right

Dyslipidemia: End Stage Renal Disease and Hemodialysis

E.Prabhakar Reddy

2009

View PDFchevron_right

Residual renal function is an independent determinant of serum FGF-23 levels in dialysis patients

Björn Meijers

Nephrology Dialysis Transplantation, 2011

View PDFchevron_right

FGF-23 removal is improved by on-line high-efficiency hemodiafiltration compared to conventional high flux hemodialysis

Marion Morena

Journal of Nephrology, 2013

View PDFchevron_right

Fibroblast Growth Factor 23 (FGF23) Predicts Progression of Chronic Kidney Disease

Ulrich Neyer

Journal of The American Society of Nephrology, 2007

View PDFchevron_right

FGF23 is associated with early post-transplant hypophosphataemia and normalizes faster than iPTH in living donor renal transplant recipients: a longitudinal follow-up study

Narayan Prasad

Clinical Kidney Journal, 2016

View PDFchevron_right